Drug intelligence / Profile preview

fenpiverinium

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intramuscular, Intravenous
01

Overview

Fenpiverinium is a small molecule anticholinergic and antispasmodic agent used primarily for the treatment of smooth muscle spasms and pain associated with gastrointestinal and urinary tract disorders[1][2][4]. It acts as a muscarinic acetylcholine receptor antagonist, inhibiting the action of acetylcholine at muscarinic receptors in smooth muscle. This leads to reduced contractions and motility in organs such as the gastrointestinal tract, providing symptomatic relief from spasms[4][5][6]. Fenpiverinium is often marketed in combination with other agents like pitofenone hydrochloride and either nimesulide or metamizole (notably under brand names such as Baralgin) in Eastern Europe and India[1][4]. The drug has been subject to regulatory changes due to safety concerns regarding its combinations. Its primary mechanism is exclusive antagonism at muscarinic acetylcholine receptors; it does not affect spontaneous phasic activity or activation by high potassium or norepinephrine[4].

Other names
fenpiverinium ionfenpiverinium cationfenpiverinium bromide
02

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on fenpiverinium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fenpiverinium.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call